The use of 4-Demethyl-4-cholesteryloxypenclomedine [DM-CHOC-PEN] as Therapy in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies Involving the Central Nervous System (CNS)
In 2020 about 89,000 adolescents and young adults (AYA) (ages 15 to 39) were estimated to be diagnosed with cancer in the United States, 23,890 had CNS and spinal nervous system (SNS) involvement—accounting for one twentieth or five percent of the number cancer diagnoses in the United States. The estimated deaths for this group was18,020 deaths in 2020 (1). This , is about eight times the number of cancers diagnosed in children ages 0 to 14 (2). The National Cancer Institute (NCI) and the American Cancer Society (ACS),in co njunction with the World Health Organization (WHO), EORTC, ECCO, and UK Cancer Foundation estimate that nearly 15% of CNS and SNS tumors worldwide involve the adolescent/ young adult (AYA) age group (3, 4).
